• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多巴反应性肌张力障碍:一例的病理和生化观察

Dopa-responsive dystonia: pathological and biochemical observations in a case.

作者信息

Rajput A H, Gibb W R, Zhong X H, Shannak K S, Kish S, Chang L G, Hornykiewicz O

机构信息

University of Saskatchewan, Saskatoon, Canada.

出版信息

Ann Neurol. 1994 Apr;35(4):396-402. doi: 10.1002/ana.410350405.

DOI:10.1002/ana.410350405
PMID:7908789
Abstract

We report the first neuropathological and neurochemical study of a patient with dopa-responsive dystonia. She had onset of foot dystonia at age 5 years and by age 8 years it was generalized with prominent right leg and arm involvement. On levodopa 750 mg daily she had complete symptomatic improvement that was sustained for 11 years until death. Pathological studies revealed normal numbers of hypopigmented substantia nigra neurons, normal tyrosine hydroxylase (TH) immunoreactivity and TH protein in the SN, no inclusion bodies or gliosis, and no evidence of a degenerative process in the striatum. Biochemical studies revealed reduced dopamine in the substantia nigra and striatum (8% in the putamen and 18% of control in the caudate) with a similar but not identical subregional distribution as in idiopathic Parkinson's disease. In the striatum, TH protein and TH activity was reduced, with the loss more pronounced in the putamen than the caudate. The GBR 12935 binding to DA transporter was normal in the caudate and at the lower end of the range of control values in the putamen. We conclude that disturbed dopamine synthetic capacity or a reduced arborization of striatal dopamine terminals may be the major disturbance in dopa-responsive dystonia.

摘要

我们报告了首例对一名多巴反应性肌张力障碍患者的神经病理学和神经化学研究。她5岁时开始出现足部肌张力障碍,8岁时病情全身性发作,右腿和右臂受累明显。每日服用750毫克左旋多巴后,她的症状完全改善,并持续了11年直至去世。病理研究显示,黑质中色素减退神经元数量正常,黑质中酪氨酸羟化酶(TH)免疫反应性和TH蛋白正常,无包涵体或胶质增生,纹状体也无退行性变过程的证据。生化研究显示,黑质和纹状体中的多巴胺减少(壳核中为对照值的8%,尾状核中为对照值的18%),其亚区域分布与特发性帕金森病相似但不完全相同。在纹状体中,TH蛋白和TH活性降低,壳核中的损失比尾状核更明显。尾状核中GBR 12935与多巴胺转运体的结合正常,壳核中的结合处于对照值范围的下限。我们得出结论,多巴胺合成能力紊乱或纹状体多巴胺终末分支减少可能是多巴反应性肌张力障碍的主要病变。

相似文献

1
Dopa-responsive dystonia: pathological and biochemical observations in a case.多巴反应性肌张力障碍:一例的病理和生化观察
Ann Neurol. 1994 Apr;35(4):396-402. doi: 10.1002/ana.410350405.
2
[Segawa disease (hereditary progressive dystonia with marked diurnal fluctuation-HPD) and abnormalities in pteridin metabolism].[Segawa病(伴有明显日波动的遗传性进行性肌张力障碍-HPD)与蝶啶代谢异常]
Rinsho Shinkeigaku. 1996 Dec;36(12):1322-3.
3
Brain biopterin and tyrosine hydroxylase in asymptomatic dopa-responsive dystonia.无症状性多巴反应性肌张力障碍中的脑生物蝶呤和酪氨酸羟化酶
Ann Neurol. 2002 May;51(5):637-41. doi: 10.1002/ana.10175.
4
[Dopa-responsive dystonia: clinical, genetic, and biochemical studies].[多巴反应性肌张力障碍:临床、遗传及生化研究]
Rinsho Shinkeigaku. 2006 Jan;46(1):19-34.
5
Alterations in expression of dopamine receptors and neuropeptides in the striatum of GTP cyclohydrolase-deficient mice.GTP环水解酶缺陷小鼠纹状体中多巴胺受体和神经肽表达的改变。
Exp Neurol. 2004 Dec;190(2):515-24. doi: 10.1016/j.expneurol.2004.08.022.
6
Molecular genetics of dopa-responsive dystonia.多巴反应性肌张力障碍的分子遗传学
Biol Chem. 1999 Dec;380(12):1355-64. doi: 10.1515/BC.1999.175.
7
[Dopa-responsive dystonia].[多巴反应性肌张力障碍]
Rinsho Shinkeigaku. 2006 Nov;46(11):769-73.
8
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.帕金森病中尾状核与壳核中5-羟色胺标志物的选择性丢失。
Brain. 2008 Jan;131(Pt 1):120-31. doi: 10.1093/brain/awm239. Epub 2007 Oct 22.
9
Is levodopa toxic to human substantia nigra?左旋多巴对人体黑质有毒性吗?
Mov Disord. 1997 Sep;12(5):634-8. doi: 10.1002/mds.870120503.
10
The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.帕金森病和亨廷顿舞蹈病中纹状体多巴胺能神经元的命运。
Brain. 2007 Jan;130(Pt 1):222-32. doi: 10.1093/brain/awl332. Epub 2006 Dec 2.

引用本文的文献

1
Clinical and Basic Research on Dopa-Responsive Dystonia: Neuropathological and Neurochemical Findings.多巴反应性肌张力障碍的临床与基础研究:神经病理学与神经化学研究结果
Juntendo Med J. 2025 Jan 30;71(1):2-10. doi: 10.14789/ejmj.JMJ24-0023-R. eCollection 2025.
2
Nine Hereditary Movement Disorders First Described in Asia: Their History and Evolution.首次在亚洲描述的九种遗传性运动障碍:其历史与演变
J Mov Disord. 2023 Sep;16(3):231-247. doi: 10.14802/jmd.23065. Epub 2023 Jun 13.
3
Crucial neuroprotective roles of the metabolite BH4 in dopaminergic neurons.
代谢物四氢生物蝶呤在多巴胺能神经元中的关键神经保护作用。
bioRxiv. 2023 May 8:2023.05.08.539795. doi: 10.1101/2023.05.08.539795.
4
Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies.帕金森病的临床表现及分子背景:基于家族性和人群研究中发现的基因
Front Neurol. 2022 Jun 2;13:764917. doi: 10.3389/fneur.2022.764917. eCollection 2022.
5
GCH1 Deficiency Activates Brain Innate Immune Response and Impairs Tyrosine Hydroxylase Homeostasis.GCH1 缺乏会激活大脑固有免疫反应并损害酪氨酸羟化酶的动态平衡。
J Neurosci. 2022 Jan 26;42(4):702-716. doi: 10.1523/JNEUROSCI.0653-21.2021. Epub 2021 Dec 7.
6
The Genetic Landscape of Parkinsonism-Related Dystonias and Atypical Parkinsonism-Related Syndromes.帕金森病相关运动障碍和非典型帕金森病相关综合征的遗传景观。
Int J Mol Sci. 2021 Jul 28;22(15):8100. doi: 10.3390/ijms22158100.
7
Dopa-responsive dystonia, DRD-plus and DRD look-alike: a pragmatic review.多巴反应性肌张力障碍、DRD-Plus 和 DRD 类似疾病:实用综述。
Acta Neurol Belg. 2021 Jun;121(3):613-623. doi: 10.1007/s13760-020-01574-1. Epub 2021 Jan 16.
8
Combined dystonias: clinical and genetic updates.合并型肌张力障碍:临床与遗传学更新。
J Neural Transm (Vienna). 2021 Apr;128(4):417-429. doi: 10.1007/s00702-020-02269-w. Epub 2020 Oct 24.
9
Mutations Associated With a Complex Phenotype Resembling Dopa-Responsive Dystonia.与类似多巴反应性肌张力障碍复杂表型相关的突变
Mov Disord Clin Pract. 2015 Apr 28;2(2):149-154. doi: 10.1002/mdc3.12144. eCollection 2015 Jun.
10
Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.遗传突触核蛋白病帕金森综合征的神经病理学:文献复习。
Mov Disord. 2017 Nov;32(11):1504-1523. doi: 10.1002/mds.27193.